Literature DB >> 15211117

The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma.

Shigeto Ueda1, Sho Ogata, Hitoshi Tsuda, Nobuaki Kawarabayashi, Mikihiko Kimura, Yoshiaki Sugiura, Seiichi Tamai, Osamu Matsubara, Kazuo Hatsuse, Hidetaka Mochizuki.   

Abstract

OBJECTIVES: Recent studies have shown that some growth factor receptors with tyrosine kinase activity, eg, the epidermal growth factor receptor (EGFr) and the c-erbB-2 (HER-2) oncoprotein, are associated with aggressive biologic behavior of various cancer cell types. We examined the clinicopathological significance of the expression and localization of EGFr and HER-2 in both invasive and intraductal components of ductal adenocarcinomas of the pancreas.
METHODS: Tissue samples from 76 archival cases of pancreatic ductal adenocarcinoma were immunohistochemically analyzed for both membrane and cytoplasmic overexpression of EGFr and HER-2 oncoprotein. The rate of incidence between the invasive and intraductal components was analyzed and then their correlation with tumor differentiation and patient prognosis was analyzed.
RESULTS: Cytoplasmic EGFr overexpression was more frequent in invasive components (47 of 76, 62%) than in intraductal components (19 of 76, 25%), while membrane EGFr overexpression was more frequent in intraductal components (41 of 76, 54%) than in invasive components (11 of 76, 14%). The membrane HER-2 overexpression was also more frequent in intraductal components (15 of 76, 20%) than in invasive components (2 of 76, 3%), but the incidence of cytoplasmic HER-2 overexpression did not differ between intraductal components (12 of 76, 16%) and invasive components (8 of 76, 11%). The cytoplasmic EGFr overexpression in invasive components was more frequent in grade 3 group (32 of 33, 97%) than in grade 2 (15 of 32, 47%) and grade 1 groups (0 of 10, 0%) (P < 0.001). Patients with adenocarcinoma with cytoplasmic EGFr overexpression showed shorter overall survival than those with adenocarcinoma without cytoplasmic EGFr overexpression (P = 0.02).
CONCLUSION: It is suggested that the cytoplasmic overexpression of EGFr plays a significant role in the progression of pancreatic ductal adenocarcinoma, especially in the invasion and acquisition of aggressive clinical behavior. Both membrane and cytoplasmic expression of HER-2 showed no significant correlation between tumor differentiation and poor survival.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15211117     DOI: 10.1097/00006676-200407000-00061

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  84 in total

1.  Polyisoprenylated methylated protein methyl esterase: a putative biomarker and therapeutic target for pancreatic cancer.

Authors:  Byron J Aguilar; Augustine T Nkembo; Randolph Duverna; Rosemary A Poku; Felix Amissah; Seth Y Ablordeppey; Nazarius S Lamango
Journal:  Eur J Med Chem       Date:  2014-05-09       Impact factor: 6.514

2.  Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.

Authors:  Nagathihalli S Nagaraj; M Kay Washington; Nipun B Merchant
Journal:  Clin Cancer Res       Date:  2011-01-25       Impact factor: 12.531

Review 3.  Genomics of pancreatic cancer: does it make any improvement in diagnosis, prognosis and therapy?

Authors:  László Kopper; Attila Zalatnai; József Tímár
Journal:  Pathol Oncol Res       Date:  2005-07-01       Impact factor: 3.201

4.  Integrative survival-based molecular profiling of human pancreatic cancer.

Authors:  Timothy R Donahue; Linh M Tran; Reginald Hill; Yunfeng Li; Anne Kovochich; Joseph H Calvopina; Sanjeet G Patel; Nanping Wu; Antreas Hindoyan; James J Farrell; Xinmin Li; David W Dawson; Hong Wu
Journal:  Clin Cancer Res       Date:  2012-01-18       Impact factor: 12.531

5.  Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies.

Authors:  Lin Chen; Ming Zhang; Shuchun Luo
Journal:  Tumour Biol       Date:  2014-08-17

6.  Epidermal growth factor down-regulates the expression of neutrophil gelatinase-associated lipocalin (NGAL) through E-cadherin in pancreatic cancer cells.

Authors:  Zhimin Tong; Subhankar Chakraborty; Bokyung Sung; Pooja Koolwal; Sukhwinder Kaur; Bharat B Aggarwal; Sendurai A Mani; Robert S Bresalier; Surinder K Batra; Sushovan Guha
Journal:  Cancer       Date:  2010-12-29       Impact factor: 6.860

7.  Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.

Authors:  Guy A Weiss; Michael R Rossi; Nikhil I Khushalani; Ken Lo; John F Gibbs; Anubha Bharthuar; John K Cowell; Renuka Iyer
Journal:  J Gastrointest Oncol       Date:  2013-03

8.  EGFR and HER2 inhibition in pancreatic cancer.

Authors:  Naomi Walsh; Susan Kennedy; AnneMarie Larkin; Brendan Corkery; Lorraine O'Driscoll; Martin Clynes; John Crown; Norma O'Donovan
Journal:  Invest New Drugs       Date:  2012-10-18       Impact factor: 3.850

9.  Erlotinib in the treatment of advanced pancreatic cancer.

Authors:  Robin K Kelley; Andrew H Ko
Journal:  Biologics       Date:  2008-03

10.  Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy.

Authors:  Bryan A Faller; Barbara Burtness
Journal:  Biologics       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.